• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Chance Pharma announces funding to support Phase 3 trial of CXG87 budesonide / formoterol DPI

DPI developer Chance Pharmaceuticals announced the completion of a financing round with participation from Heda Health Fund and Qihang Venture Capital, with proceeds intended to support Phase 3 trials of CXG87 inhaled dry powder budesonide / formoterol as well as development of some additional DPI formulations. The company did not specify the amount raised. Chance … [Read more...] about Chance Pharma announces funding to support Phase 3 trial of CXG87 budesonide / formoterol DPI

Polyrizon announces development of intranasal naloxone and agreement to develop intranasal formulation of a psychedelic therapy

Israeli biotech Polyrizon announced that it is beginning preclinical development of an intranasal naloxone formulation based on the company's Trap and Target mucoadhesive technology. The company said that Fabio Sonvico of the University of Parma, who is a member of Polyrizon's scientific advisory board, will conduct the studies. Polyrizon CEO Tomer Izraeli … [Read more...] about Polyrizon announces development of intranasal naloxone and agreement to develop intranasal formulation of a psychedelic therapy

Armata announces $10 million loan from Innoviva to fund development of candidates including AP-PA02 inhaled phage therapy

Armata Pharmaceuticals announced details of an additional secured credit agreement with Innoviva Strategic Opportunities, the company's largest shareholder. Armata said that it will pay interest at a 14% annual rate on the $10 million loan which matures on March 12, 2026. According to the announcement, the funds will be used for continued development of candidates … [Read more...] about Armata announces $10 million loan from Innoviva to fund development of candidates including AP-PA02 inhaled phage therapy

Emergent BioSolutions and Rocketvax form joint venture for development of intranasal vaccine candidates

Emergent BioSolutions and Swiss biotech Rocketvax have announced that Emergent will make a strategic investment in Rocketvax parent company Swiss Rockets and will take over manufacturing and commercialization activities for 4 of Rocketvax's intranasal vaccine candidates. Rocketvax's pipeline includes live attenuated intranasal vaccines for melanoma and multiple … [Read more...] about Emergent BioSolutions and Rocketvax form joint venture for development of intranasal vaccine candidates

Altamira gets US patent covering Bentrio bentonite nasal spray formulation

Altamira Therapeutics said that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for a patent covering the formulation of Bentrio bentonite-based nasal spray. Bentrio received 510(k) clearance in the US in June 2022. In 2023, the company sold a 51% stake in its subsidiary Altamira Medica, which developed Bentrio for the prevention … [Read more...] about Altamira gets US patent covering Bentrio bentonite nasal spray formulation

Iconovo gets SEK 670,000 Innowwide grant to explore selling its DPIs and services in the Japanese market

According to DPI developer Iconovo, the company has received a grant worth SEK 670,000 from the EU's Innowwide initiative, which encourages small and medium-sized EU companies to enter international markets. The grant will fund a market study this year that will evaluate opportunities for Iconovo to partner with Japanese companies to sell its products and services in … [Read more...] about Iconovo gets SEK 670,000 Innowwide grant to explore selling its DPIs and services in the Japanese market

Silo Pharma announces additional US patent related to SPC-15 intranasal ketamine

According to Silo Pharma, the US Patent and Trademark Office (USPTO) has indicated that it will issue a new patent on March 4, 2025 that will provide protection for Silo's SPC-15 intranasal ketamine. The company says that the expected patent number for the patent titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females” is … [Read more...] about Silo Pharma announces additional US patent related to SPC-15 intranasal ketamine

Renaissance Lakewood to provide development services for Tiziana’s intranasal foralumab

Tiziana Life Sciences announced that it has contracted with CDMO Renaissance Lakewood for development services related to Tiziana's intranasal foralumab anti-CD3 monoclonal antibody. According to Tiziana, the project includes optimization of the formulation and development of "a comprehensive plan for the scale-up of foralumab in a nasal device." Tiziana is … [Read more...] about Renaissance Lakewood to provide development services for Tiziana’s intranasal foralumab

Kyorin gets option to license Cyrano’s CYR-064 intranasal theophylline for the Japanese market

Kyorin Pharmaceutical is paying an undisclosed fee for the option to license Japanese development and marketing rights to Cyrano Therapeutics' CYR intranasal theophylline for the treatment of loss of smell, the companies said. A Phase 2 trial of the nasal spray in patients with post-viral hyposmia that was initiated in 2023 is still underway. According to the … [Read more...] about Kyorin gets option to license Cyrano’s CYR-064 intranasal theophylline for the Japanese market

Ethris gets $5 million from CEPI for development of spray-dried RNA vaccines for nasal delivery

The Coalition for Epidemic Preparedness Innovations (CEPI) is providing $5 million to inhaled RNA developer Ethris for development of spray-dried RNA vaccines for nasal delivery. Ethris said that it plans to focus initially on a vaccine against influenza once a successful process is established. Within the past few months, CEPI also provided funding to an Abera … [Read more...] about Ethris gets $5 million from CEPI for development of spray-dried RNA vaccines for nasal delivery

  • « Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews